<DOC>
	<DOCNO>NCT01709162</DOCNO>
	<brief_summary>The purpose study determine whether additional dos ipilimumab positive effect survival treatment advance melanoma progress successful initial treatment ipilimumab .</brief_summary>
	<brief_title>Study Compare Effect Ipilimumab Retreatment With That Chemotherapy Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Key Histologic diagnosis unresectable stage III IV metastatic melanoma Prior ipilimumab induction treatment ( 3 mg/kg ) Documented disease control [ Stable Disease â‰¥3 month Partial Response/Complete Response ] ipilimumab induction Documented progressive disease follow disease control Key Patients brain metastasis exclude , unless free neurologic symptom relate metastatic brain lesion receive systemic corticosteroid therapy purpose reduce intracranial inflammation 10 day prior begin retreatment ipilimumab Any intervening anticancer therapy last dose ipilimumab induction ipilimumab retreatment study Patients experience grade 3 immunerelated adverse event ( irAE ) ( except endocrinopathies clinical symptom control appropriate hormone replacement therapy ) grade 4 toxicity prior treatment ipilimumab Patients prior irAE improve grade 1 good randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>